Rakuten Medical’s Post

First follow-up of neoadjuvant cemiplimab in SCC published last October 2023. 📍 This single arm, multicentre, phase 2 study demonstrated a high rate of pathological complete response (51%) among patients with resectable cutaneous squamous cell carcinoma who received neoadjuvant cemiplimab. 🤓 📍 Results from this follow-up analysis further support the safety and clinical activity of perioperative cemiplimab, with encouraging event-free survival in patients with any degree of pathologic response. 🤓 https://lnkd.in/g2PUuGfP #neoadjuvantimmunotherapy #skincancerdoctor #nonmelanomaskincancer #medicaloncologist

May is Brain Tumor Awareness Month – a month to raise awareness and acknowledge the progress of #GBMAGILE, a clinical trial for patients with #glioblastoma. GBM AGILE enables multiple drugs (and combinations of drugs) to be screened simultaneously and over time, revolutionizing the way new therapies are developed. To learn more about this innovative trial, visit: gcaresearch.org #GoGrayinMay #BTAM #BrainTumorAwarenessMonth

Baseline differences in metabolic profiles of patients with lung squamous cell carcinoma responding or not responding to treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) https://lnkd.in/e5_Skwv2

Be sure to read this #clinicalinvestigation 🔍 #Percutaneous Microwave #Ablation Versus Robot-Assisted Partial Nephrectomy for Stage I Renal Cell Carcinoma: A Propensity-Matched Cohort Study Focusing Upon Long-Term Follow-Up of Oncologic Outcomes https://lnkd.in/dPfTsF2C

Going to #ESMO23? We will be there from Oct 20-23. Come to booth 726a and explore the past, present, and potential future treatment options for unresectable hepatocellular carcinoma (uHCC). Plus, you can make an appointment to discuss the latest data. See you soon! https://hubs.ly/Q024bqv90 #ElevatingOutcomes #EveryMeasureMatters #ElevarAtESMO23

This Unusual Case of Impending Paradoxical Embolism is a Must-Read for Physicians! A rare tumor embolus from renal cell carcinoma caused an impending paradoxical embolus through a PFO. Learn how these physicians managed this clinical emergency. #medicine #cardiology #oncology Read the full case report here: https://lnkd.in/g9szgQ-7 Don't miss this fascinating medical case that provides key insights into managing paradoxical embolism, a rare but serious condition. Stay updated on the latest clinical research by following us. #medicalresearch #rarecases #casestudy

Can ⁶⁸Ga-FAPI serve as a predictive biomarker for unresectable hepatocellular carcinoma? https://ow.ly/KVc750PrNgp #NuclearMedicine #PETscan #HeptocellularCarcinoma

At #ASCO24, we spoke with Peter R. Galle, MD, PhD, of Universitätsmedizin Mainz on the results of CheckMate-9DW for unresectable hepatocellular carcinoma. Learn how #nivolumab plus #ipilimumab fared against #sorafenib and #lenvatinib as a first-line treatment: https://buff.ly/4c4hO69

✨Behind the Scenes at GC Cell: Delivering Hope✨ Proud to highlight the recent media coverage detailing the remarkable 24-hour "vein-to-vein" journey of #Immuncell-LC, our pioneering autologous CIK T cell therapy for adjuvant hepatocellular carcinoma (HCC). This comprehensive reportage captures the essence of our commitment to transforming patient care through innovation. Our dedicated team works tirelessly, often during off-hours, ensuring that #Immuncell-LC is delivered with the highest viability directly to hospitals across the country—from production to patient in under 36 hours. This logistical precision underpins our ability to offer not just treatment, but renewed optimism to patients battling cancer. The journey of #Immuncell-LC is more than a process; it's a promise of quality, care, and hope, ensuring that every patient receives the best possible chance at recovery. This is our purpose and aspiration. 👉Link to the reportage: (Original in Korean) https://bit.ly/45hNrGN (Autotranslated in Eng) https://bit.ly/3V3TTwf #GCCell #eachandeverypatient #CellTherapy #Biotechnology #PatientCare #HCCAwareness #CGT #vision #commitment